featured-image

In a recent study published in Kidney International Reports , researchers investigated the effects of semaglutide (administered once weekly) on kidney disease outcomes and changes in KDIGO (short for kidney disease improving global outcomes) risk categories in participants with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or high cardiovascular (CV) risk. They found that as compared to the placebo, the administration of semaglutide (once weekly) reduced the risk of kidney disease and altered KDIGO risk categories, regardless of KDIGO risk at the baseline. Study: Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial .

Image Credit: myskin/Shutterstock.com Diabetes is a major cause of chronic kidney disease (CKD) and kidney failure, with 40% of T2D patients developing CKD. Those with T2D and CKD face high CV risks, including atherosclerotic CV disease and heart failure.



GLP-1 (short for glucagon-like peptide 1) receptor agonists (GLP-1RAs) are used in T2D treatment for their benefits on hyperglycemia, weight management, and CV safety. Some show improved CV outcomes and beneficial effects on kidney disease, such as reducing albuminuria and slowing kidney function loss. In the trial SUSTAIN 6 (short for trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with T2D), weekly semaglutide could significantly reduce the risk of major CV events and secondary kidney disease .

Back to Health Page